Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 42-45

  Fleming, Gini F ^a   Waggoner, Steven E ^a   Rotmensch, Jacob ^a   Skoog, Linda A ^a   Langhauser, Carole ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031127610     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4622     Document Type: Article

References (21)

1. 1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. 2. Thigpen JT: Chemotherapy in the Management of Celomic Epithelial Carcinoma of the Ovary, in Markman M, Hoskins W (eds): Cancer of the Ovary. New York, Raven Press, Chap 20, pp 277-286
3. 3. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405-2410, 1993
4. 4. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbino FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
5. 5. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
6. 6. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
7. 7. Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
8. 8. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785, 1995
9. 9. Semrad N, Chung F, Latino F, Watring WG: Multi-agent constant infusion chemotherapy in gynecologic oncology patients. Proc Am Soc Clin Oncol 13:264, 1994
10. 10. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993
11. 11. Muss HB: Gynecologic Malignancy, in Lokich JL (ed): Cancer Chemotherapy by Infusion. Chicago, Precept Press, 1987, Chap 28, pp 368-379
12. 12. Lai G-M, Chen Y-N, Mickley LA, Fojo AT, Bates SE: P-Glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:696-673, 1991
13. 13. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukimoto M: Expression of the multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54:1355-1359, 1994
14. 14. Van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PHB, Aalders JG, de Vries EGE: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
15. 15. Izquierdo MA, Ate GJ, van der Zee, Vermerken JB, van der Valk D, Belien JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230-1237, 1995
16. 16. van der Zee AGJ, Hollema HH, de Buijn HWA, Willemse PHB, Boonstra H, Mulder NH, Aalders JG, de Vries EGE: Cell biological markers of drug resistance in ovarian carcinoma. Gyn Oncol 58:165-178, 1995
17. 17. Sonis ST: Oral Complications of Cancer Therapy, in Rubin D (ed): Cancer Principles and Practice of Oncology. Philadelphia, Lippincott, 1993, Sect 6, pp 2385-2394
18. 18. Rugg T, Saunders MI, Dische S: Smoking and mucosal reactions to radiotherapy. Br J Radiat 63:554-556, 1990
19. 19. Eisenhauer EA, ten Bokkel Huinik WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermerken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
20. 20. Pearl ML, Yashar CM, Johnston CM, Reynolds RK, Roberts JA: Exponential regression of CA 125 during salvage treatment of cancer with taxol. Gyn Oncol 53:339-343, 1994
21. 21. Rustin GJS, van der Burg MEL, Berek JS: Tumour markers. Ann Oncol 4:S71-S77, 1993